Clinical Trial

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / NSMP EC
Protocol Amendment History 4 changes
notable Trial sites expanded: 114 -> 118 locations 2026-08-12
notable Trial sites expanded: 110 -> 114 locations 2026-07-15
notable Trial sites expanded: 105 -> 108 locations 2026-05-13
notable Trial sites expanded: 100 -> 105 locations 2026-04-15
Trial Details
NCT Number NCT05640999
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Canadian Cancer Clinical Trials Network, Australia New Zealand Gynaecological Oncology Group, Gustave Roussy, Cancer Campus, Grand Paris, Leiden University Medical Center, Mario Negri Gynecologic Oncology group (MaNGO), NRG Oncology, Philipps University Marburg
Conditions Endometrial Cancer
Enrollment 393 participants
Start Date 2022-12-19
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-11